1[1]Greenberg B,Borghi C,Perrone S.Pharmacotherapeutic approaches for decompensated heart failure:a role for the calcium sensitiser,levosimendan?[J].The European Journal of Heart Failure,2003,5(1):13-21.
2[2]Papp Z,Csapo K,Pollesello P,et al.Pharmacological mechanisms contributing to the clinical efficacy of levosimendan[J].Cardiovasc Drug Rev,2005,23(1):71-98.
3[3]Lepran I,Papp JG.Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats[J].European Journal of Pharmacology,2003,464(2～3):171-176.
4[4]Auslender M.New drugs in the treatment of heart failure[J].Progress in Pediatric Cardiology,2000,12(1):119-124.
5[5]Ajiro Y,Hagiwara N,Katsube Y,et al.Levosimendan increases L-type Ca2+ current via phosphodiesterase-3 inhibition in human cardiac myocytes[J].European Journal of Pharmacology,2002,435(1):27-33.
6[6]Takahashi R,Talukder MA,Endoh M.Inotropic effects of OR-1896,an active metabolite of levosimendan,on canine ventricular myocardium[J].European Journal of Pharmacology,2000,400(1):103-112.
8[8]Avgeropoulou C,Andreadou I,Markantonis-Ky roudiss,et al.The Ca2+-sensitizer levosimendan improves oxidative damage,BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine[J].Eur J Heart Fail,2005,7(5):882-887.
9[9]Pataricza J,Hohn J.Comparison of the vasorelaxing effect of cromokalim and the new inodilator,levosimendan,in human isolated portal vein[J].J Pharm Pharmacol,2000,52(2):213-219.
10[10]Lochner A,Colesky F,Genade S.Effect of a calcium-sensitizing agent,levosimendan,on the postcardioplegic inotropic response of the myocardium[J].Cardiovasc Drugs Ther,2000,14(3):271-281.
同被引文献9
1Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guidline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,62(16):147-239.
2Dickstein K,Cohen-Solal A,Filippatos G,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008.The task force for the diagnosis and treatment of acute and Chronic Heart Failure.2008 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC(HFA)and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur J Heart Fail,2008,10(10):933-989.
3Pathak A,Lebrin M,Vaccaro A,et al.Pharmacology of levosimendan:inotropic,vasodilatory and cardioprotective effects[J].J Clin Pharm Ther,2013,38(5):341-349.
4Nieminen MS,Fruhwald S,Heunks LM,et al.Levosimendan:current data,clinical use and future development[J].Heart Lung Vessel,2013,5(4):227-245.
5Follath F,Cleland JG,Just H,et al.Effi cacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study):a randomized double-blind trial[J].Lancet,2002,360(9328):196-202.
6Silva-Cardso J,Ferreira J,Oliveira-Soares A,et al.Effectiveness and satety of levosimendan in clinical practice[J].Rev Port Canliol,2009,28(2):143-154.
